US Trastuzumab Competition Heats Up
Mylan And Biocon’s Ogivri Biosimilar Leads New Wave Of Herceptin Rivals
Mylan and Biocon have launched their Ogivri trastuzumab biosimilar in the US, marking the second biosimilar rival to Herceptin and leading a new wave of trastuzumab biosimilars expected to arrive in the US early next year.
You may also be interested in...
Biocon-Mylan’s sBLA for pegfilgrastim made at a new Indian site gets an FDA go-ahead, facilitating a "multi-fold" scale up in capacity. But it will be interesting to watch how impactful this could be on market dynamics in the US, where more competition has arrived.
Teva says it is on track to achieve both its sales targets and its restructuring goals as it prepares to enjoy the benefits of being first to market with a rituximab biosimilar in the US.
Mylan is preparing to launch a trastuzumab biosimilar in the US, while progress of developing bevacizumab and aflibercept biosimilars continues. Insulin aspart and glargine are also in Mylan’s pipeline.